Psilocybin: Understanding the Chemistry, Pharmacology, Dosage, and Effects
Psilocybin has garnered increasing attention in recent years, both in scientific research and public discourse. This blog post aims to provide a deep understanding of the chemistry, pharmacology, dosage, and diverse effects of psilocybin. We will explore its chemical properties, physiological effects, and resulting impacts. Keep reading if you want to learn all about the primary compound in Magic Mushrooms!
What is Psilocybin?
Psilocybin is a naturally occurring psychedelic found in certain mushroom species, commonly known as Magic Mushrooms or Shrooms. It is renowned for its psychoactive properties, leading to extensive study in psychopharmacology. With a history dating back to indigenous peoples of Central and South America, who used it for religious and spiritual purposes, psilocybin is now under modern medical scrutiny for its therapeutic potential, especially in treating mental disorders like depression and anxiety.
The Basics of Psilocybin and Its Role in Medicine
Psilocybin converts to psilocin in the body, which is its pharmacologically active form. This conversion allows psilocin to reach the brain and interact with serotonin receptors, making psilocybin a promising substance in treating various mental illnesses. Researchers aim to explore new avenues for symptom relief and root cause mitigation.
Psilocybin vs. Psilocin: A Look at Conversion
Upon ingestion, psilocybin rapidly converts to psilocin through enzymatic action in the human body, although this reaction can also occur within the mushrooms themselves. This biochemical process is crucial for the psychotropic effects users experience. Psilocin bears structural similarity to the neurotransmitter serotonin (5-HT), enabling psilocybin to bind to specific serotonin receptors, particularly the 5-HT2A receptor, resulting in perceptual and consciousness alterations. Notably, non-natural prodrugs of psilocin, like Psilacetin (4-AcO-DMT), find utility in pharmaceutical research and among research chemical vendors, circumventing legal restrictions and simplifying production without altering the ultimate active compound.
The Chemistry of Psilocybin
The chemical composition of psilocybin and its resultant psychotropic effects make it a subject of intense scientific research and discourse.
Structure and Properties
Psilocybin, based on the core structure of N,N-Dimethyltryptamine (DMT), is a derivative thereof, belonging to the class of indoles, a heterocyclic and aromatic framework. Notably, the functionalization at the 4-position of the indole is rare in nature. Psilocybin exists as a zwitterion due to the combination of an amine with a phosphoester within the molecule, enhancing water solubility. Unlike psilocybin, psilocin lacks this property, facilitating their chromatographic separation. Both compounds, possessing the indole framework, can be detected using the Ehrlich reagent, forming a pink to purple dye.
A Unique Chemical Property of Psilocin
In contrast to other psychoactive substances, psilocin's hydroxylation at the 4-position of the indole ring enables it to engage in an additional weak self-binding, an intramolecular hydrogen bond. This enhances psilocin's membrane permeability, allowing it to easily cross the blood-brain barrier and reach the brain. For instance, structurally similar Bufotenin (5-OH-DMT) lacks this property, requiring very high doses for effects despite its high affinity for serotonin receptors.
The Pharmacology of Psilocybin / Psilocin in the Brain
The pharmacology of psilocin is complex and fascinating, deeply intertwining with the neurochemistry of the human brain. This section delves into receptor interactions, metabolism, and substance excretion, providing a scientific framework for understanding these processes.
Receptor Effects
Once psilocin, the active metabolite of psilocybin, enters the brain, it primarily acts on serotonin receptors, particularly the 5-HT2A receptor, responsible for its psychoactive properties. Administering Ketanserin, a selective antagonist of the 5-HT2A receptor, can negate the psychedelic effects of psilocin. It's important to note that psilocin also binds to other receptors, such as those implicated in increased neuroplasticity, primarily driving therapeutic effects, an area of active research.
Metabolism and Excretion
After exerting its effects in the brain, psilocin undergoes metabolism, crucial for the duration of action. The metabolites produced in the body are no longer psychoactive. The primary metabolic pathway involves monoamine oxidase (MAO)-mediated amine cleavage, followed by enzymatic oxidation or reduction of the aldehyde. Approximately 80% of psilocin is metabolized via O-glucuronidation and excreted through urine.
Dosage of Psilocybin
Dosage plays a crucial role in the safety and efficacy of psilocybin use. Precise dosing can maximize therapeutic benefits while minimizing adverse effects. This section discusses the dose-response relationship, dosage guidelines, and safety considerations.
Understanding the Dose-Response Relationship
The perceived effects of psilocybin are complex, influenced by individual factors, primarily set and setting, and dosage. Higher psilocybin doses lead to more intense subjective experiences, ranging from perceptual alterations to ego dissolution. However, this relationship isn't linear, as psychological disposition and environment significantly influence outcomes. The intensity of perceived effects of psilocybin/psilocin doesn't correlate with gender and weight, factors often considered in medication dosing.
Studies indicate dose-dependent occupancy of 5-HT2A receptors, indicating a close link between dose, psilocin plasma levels, and psychedelic experience intensity, crucial for clinical applications.
Psilocybin Toxicity - The Dose Makes the Poison
Numerous clinical and toxicological studies demonstrate psilocybin's low toxicity, causing no organ damage or neurotoxic effects. The median lethal dose (LD50) for rats and mice is 280-285mg/kg. Considering an average 0.1% active ingredient content in fresh mushrooms, consuming over 21 kg of fresh or 2.1 kg of dried mushrooms would be necessary to reach the median lethal dose in a 75 kg person. Psilocybin's long history of consumption as psychedelic mushrooms hasn't led to documented physical harm from the compound.
Magic Mushrooms Dosage
Dosing magic mushrooms is complex, as it's not only the amount of consumed psilocybin that's crucial but also the likely presence of other pharmacologically active compounds in the magic mushrooms. In addition to psilocybin, these mushrooms contain a range of other substances, including tryptamine alkaloids, ß-carbolines, and terpenes, which could influence the psychopharmacological profile and effects of the mushrooms (Blei, 2020; Schäfer et al., 2023). The hypothesis is that all these and additional compounds modulate the intensity and quality of the psychedelic experience, meaning that the same amount of psilocybin in different mushroom species can lead to different effects.
For those interested in learning more about the complex interactions between the various compounds present in magic mushrooms, the miraculix blog "The Entourage Effect: The Potential of Full-Spectrum Magic Mushrooms" offers in-depth insights. There, the various psychoactive components and their potential effects on the experience with psilocybin are described in detail. This knowledge can be important for users to make an informed decision about the use and dosage of psilocybin-containing mushrooms.
The Effects of Psilocybin
Psilocybin, a naturally occurring psychedelic, is known for its intense psychological and physical effects. In this section, we will examine the multifaceted effects of psilocybin on the human body and mind.
Psychedelic Effects and Duration of Action
The psychedelic effects of psilocybin are diverse and can range from mild sensory alterations to profound changes in perception and consciousness (Geiger et al., 2018). These effects typically begin within 20 to 40 minutes after ingestion and peak at around 60 to 90 minutes. The total duration of action can vary between 4 and 8 hours, depending on the dosage, the individual physiology of the consumer, and other factors such as ingestion on a full or empty stomach (Dodd et al., 2023).
Psychotropic and Neuropsychological Effects
On a psychotropic level, psilocybin can lead to intensification of thoughts, increased emotional sensitivity, and alteration of time perception. Users often report a sense of connectedness with the environment and dissolution of the ego, leading to altered self-perception (Dodd et al., 2023). Neuropsychologically, psilocybin can influence cognitive processes, resulting in increased creativity and openness to new experiences. However, these effects are subjective and can vary significantly from person to person.
Physical Reactions and Side Effects
Physically, ingesting psilocybin can lead to symptoms such as muscle relaxation or stiffness, changes in heart rate and blood pressure, and gastrointestinal discomfort such as nausea. Some users also report a sensation of weightlessness or physical distortions. Although psilocybin is generally considered safe, higher doses can lead to side effects such as panic reactions or dysphoric states, especially when consumed in a non-supportive environment.
Frequently Asked Questions (FAQ)
The pharmacology of psilocybin is complex and not yet fully understood. Psilocybin is a psychoactive substance found in certain mushroom species, known as magic mushrooms. After ingestion, psilocybin is metabolized in the body into psilocin, which is the actual psychoactive component. Psilocin primarily acts on the serotonin receptor 5-HT2A in the brain, but likely also on a number of other receptors. This results in a range of psychological effects, ranging from visual hallucinations to profound changes in perception and consciousness.
The duration of psilocybin's effects can vary but depends on several factors, including dosage, individual metabolism, and method of ingestion. Generally, the effects of psilocybin typically begin about 20 to 40 minutes after ingestion and can last between 4 and 6 hours. The strongest effects typically occur between 1 and 2 hours after ingestion.
Magic mushrooms and psilocybin are generally not considered addictive since they do not cause physical dependence (Van der Meer et al., 2023). One can develop a short-term tolerance to psilocybin, for example, if taking magic mushrooms two days in a row, it may produce little to no effects on the second day. Unfortunately, there are few current scientific studies on psilocybin tolerance, but generally, it is said that after 4-6 weeks, tolerance dissipates. However, the psychological urge to repeat the experience can lead to problematic patterns for some users. It's important to be aware of the potential risks and to handle these substances responsibly.
Serotonin syndrome is a potentially life-threatening reaction that occurs when too much serotonin accumulates in the brain. It can be triggered by the misuse of serotonergic drugs, including psilocybin, especially when combined with other substances that affect the serotonin system. Serotonin syndrome mainly occurs when multiple serotonergic drugs are combined, such as psilocybin and antidepressants (selective serotonin reuptake inhibitors, SSRIs). Symptoms can include restlessness, hallucinations, fever, fluctuations in blood pressure and heart rate, and, in severe cases, seizures and loss of consciousness. If taking medications, it's always important to discuss with your doctor before consuming psychedelics like psilocybin!
The detectability of psilocybin in urine depends on several factors, including the dose taken and individual metabolic rate. Generally, psilocybin can be detected in urine for a short period of 24 to 48 hours. However, this period may be extended with higher doses or in individuals with a slower metabolism. It's worth noting that standard drug tests do not detect psilocybin; specialized tests are required for this purpose.
Sources
Blei, F. (2020). Untersuchungen zur Biosynthese von Indolalkaloiden aus den Basidiomyceten der Gattung Psilocybe. https://doi.org/10.22032/dbt.46039
Cerletti, A. (1958). "Etude pharmacologique de la psilocybine." Paris, Muséum national d'Histoire naturelle: 268-271.
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023). Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS Spectrums, 28(4), 416–426. https://doi.org/10.1017/S1092852922000888
Geiger, HA, Wurst, MG, Daniels, RN. DARK classics in chemical neuroscience: psilocybin. ACS Chem Neurosci. 2018;9(10):2438–2447. doi:10.1021/acschemneuro.8b00186
Halberstadt, A. L., et al. (2011). "Differential contributions of serotonin receptors to the behavioral effects of indoleamine hallucinogens in mice." Journal of Psychopharmacology 25(11): 1548-1561.
Hasler, F., Bourquin, D., Brenneisen, R., & Vollenweider, F. X. (2002). Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. Journal of Pharmaceutical and Biomedical Analysis, 30(2), 331–339. https://doi.org/10.1016/s0731-7085(02)00278-9
Hirschfeld, T., & Schmidt, T. T. (2021). Dose–response relationships of psilocybin-induced subjective experiences in humans. Journal of Psychopharmacology, 35(4), 384–397. https://doi.org/10.1177/0269881121992676
Hofmann, A. "Psychotomimetic agents."New York: Dekker ,(1968).
Johnson, M. W., et al. (2008). "Human hallucinogen research: guidelines for safety." Journal of Psychopharmacology 22(6): 603-620.
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., Erritzoe, D., Ozenne, B., & Knudsen, G. M. (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 44, 1328–1334. https://doi.org/10.1038/s41386-019-0324-9
Nichols, D. E. (2004). "Hallucinogens." Pharmacology & Therapeutics 101(2): 131-181.
Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002). The pharmacology of psilocybin. Addiction Biology, 7(4), 357–364. https://doi.org/10.1080/1355621021000005937
Ray, T. S. (2010). "Psychedelics and the human receptorome." PloS One 5(2): e9019.
Schäfer, E., Seibold, P. S., Bartram, S., Trottmann, F., Haensch, V. G., Gressler, M., Chadeayne, A., Hertweck, C., O’Connor, S. E., & Hoffmeister, D. (2023). A „Magic Mushroom“ Multi‐Product sesquiterpene synthase. ChemBioChem, 24(21). https://doi.org/10.1002/cbic.202300511
Usdin, E. and D. H. Efron (1972). "Psychotropic drugs and related compounds, National Institute of Mental Health. " 72(9074): 1-790
Van Der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., De Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., & Batalla, A. (2023). Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1134454